MAIN STORY
How the court reached its decision
Justice Dale La Hood set aside regulations adopted in 2025 that would have barred new prescriptions of gonadotropin-releasing hormone (GnRH) analogues for patients under 18 with gender dysphoria or gender incongruence. The decision followed judicial review proceedings brought by the Professional Association for Transgender Health Aotearoa (PATHA) against Health Minister Simeon Brown. The judgment concerned both legal process and the substance of the restrictions.
A central flaw lay in consultation. Organizations consulted by the Ministry of Health had not been clearly told that a complete ban on new prescriptions was under consideration. The court also found insufficient urgency to justify failing to consult gender-diverse young people directly. Those affected by a far-reaching policy, the reasoning suggests, cannot be treated as a peripheral voice when its scope is being determined.
Equality rights meet contested medical evidence
The rules distinguished between medical uses of the same medication. Puberty blockers remained available for some other conditions, including precocious puberty, and for patients who had already started treatment.














